Kongsaengdao, S.; Arayawichanont, A.; Samintharapanya, K.; Rojanapitayakorn, P.; Maneeton, B.; Maneeton, N.
A 12-Week Prospective, Double-Blind, Multicenter, Randomized Study Comparing 100 Units of Abobotulinum Toxin Type A (Dysport®) and 33.33 Units of Neubotulinum Toxin Type A (Neuronox®) for the Treatment of Hemifacial Spasm. Toxins 2025, 17, 173.
https://doi.org/10.3390/toxins17040173
AMA Style
Kongsaengdao S, Arayawichanont A, Samintharapanya K, Rojanapitayakorn P, Maneeton B, Maneeton N.
A 12-Week Prospective, Double-Blind, Multicenter, Randomized Study Comparing 100 Units of Abobotulinum Toxin Type A (Dysport®) and 33.33 Units of Neubotulinum Toxin Type A (Neuronox®) for the Treatment of Hemifacial Spasm. Toxins. 2025; 17(4):173.
https://doi.org/10.3390/toxins17040173
Chicago/Turabian Style
Kongsaengdao, Subsai, Arkhom Arayawichanont, Kanoksri Samintharapanya, Pichai Rojanapitayakorn, Benchalak Maneeton, and Narong Maneeton.
2025. "A 12-Week Prospective, Double-Blind, Multicenter, Randomized Study Comparing 100 Units of Abobotulinum Toxin Type A (Dysport®) and 33.33 Units of Neubotulinum Toxin Type A (Neuronox®) for the Treatment of Hemifacial Spasm" Toxins 17, no. 4: 173.
https://doi.org/10.3390/toxins17040173
APA Style
Kongsaengdao, S., Arayawichanont, A., Samintharapanya, K., Rojanapitayakorn, P., Maneeton, B., & Maneeton, N.
(2025). A 12-Week Prospective, Double-Blind, Multicenter, Randomized Study Comparing 100 Units of Abobotulinum Toxin Type A (Dysport®) and 33.33 Units of Neubotulinum Toxin Type A (Neuronox®) for the Treatment of Hemifacial Spasm. Toxins, 17(4), 173.
https://doi.org/10.3390/toxins17040173
